Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287988 · ClinicalTrials.gov registry record
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies
A clinical trial, sponsored by ThromboGenics.
- Completed
- Registry status
- 24
- Enrollment target
NCT01287988: Completed study, sponsored by ThromboGenics.
NCT01287988 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01287988 has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
Primary Outcome
Consenting patients will attend one visit, at which an ocular history, visual acuity (ETDRS) and full ophthalmologic assessment, as well as SD-OCT, and ERG assessment will be obtained. All SD-OCTs and ERGs will be centrally read by a masked and independent central reader.
Interventions
- DRUG placebo
- DRUG ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
What the finished NCT01287988 record still lists
NCT01287988 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01287988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01287988 about?
NCT01287988 is a clinical study titled "Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies". The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).
What is the current status of trial NCT01287988?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2011-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01287988?
The interventions under investigation include: placebo (DRUG), ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT01287988?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia